TaiGen Biopharmaceuticals Holdings (ROCO:4157) Debt-to-Equity : 0.06 (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is TaiGen Biopharmaceuticals Holdings Debt-to-Equity?

TaiGen Biopharmaceuticals Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$16.1 Mil. TaiGen Biopharmaceuticals Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$54.7 Mil. TaiGen Biopharmaceuticals Holdings's Total Stockholders Equity for the quarter that ended in Mar. 2024 was NT$1,109.6 Mil. TaiGen Biopharmaceuticals Holdings's debt to equity for the quarter that ended in Mar. 2024 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for TaiGen Biopharmaceuticals Holdings's Debt-to-Equity or its related term are showing as below:

ROCO:4157' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.04 Max: 0.1
Current: 0.06

During the past 13 years, the highest Debt-to-Equity Ratio of TaiGen Biopharmaceuticals Holdings was 0.10. The lowest was 0.00. And the median was 0.04.

ROCO:4157's Debt-to-Equity is ranked better than
69.62% of 1060 companies
in the Biotechnology industry
Industry Median: 0.14 vs ROCO:4157: 0.06

TaiGen Biopharmaceuticals Holdings Debt-to-Equity Historical Data

The historical data trend for TaiGen Biopharmaceuticals Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiGen Biopharmaceuticals Holdings Debt-to-Equity Chart

TaiGen Biopharmaceuticals Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.08

0.04

0.07

TaiGen Biopharmaceuticals Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.03	0.09	0.09	0.07	0.06

Competitive Comparison of TaiGen Biopharmaceuticals Holdings's Debt-to-Equity

For the Biotechnology subindustry, TaiGen Biopharmaceuticals Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TaiGen Biopharmaceuticals Holdings's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiGen Biopharmaceuticals Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where TaiGen Biopharmaceuticals Holdings's Debt-to-Equity falls into.

TaiGen Biopharmaceuticals Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

TaiGen Biopharmaceuticals Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(15.977	+	58.71)	/	1118.898
	=	0.07

TaiGen Biopharmaceuticals Holdings's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(16.063	+	54.661)	/	1109.607
	=	0.06

TaiGen Biopharmaceuticals Holdings (ROCO:4157) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

TaiGen Biopharmaceuticals Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of TaiGen Biopharmaceuticals Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

TaiGen Biopharmaceuticals Holdings (ROCO:4157) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiGen Biopharmaceuticals Holdings Ltd (ROCO:4157) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 138 Xinming Road, 114th Floor, Neihu District, Taipei, TWN, 114

Website

https://www.taigenbiotech.com/tw

TaiGen Biopharmaceuticals Holdings Ltd is a market-oriented pharmaceutical Research and development company with R and D as the core, committed to the development of anti-infective drugs. The company has a subsidiary in Beijing to conduct clinical trials and registration of new drugs in China.

TaiGen Biopharmaceuticals Holdings (ROCO:4157) Headlines

No Headlines